

## Vitae Pharmaceuticals Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 07-Mar-2015

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

    Phase 2 Clinical..... 11

    Phase 1 Clinical..... 15

    Discovery..... 26

[Return to Table of Contents](#)

# Vitae Pharmaceuticals Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Vitae Pharmaceuticals Inc
<b>Parent Company Name</b>	Vitae Pharmaceuticals Inc
<b>Website</b>	http://www.vitaepharma.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	7
<b>Number of Inactive Drugs</b>	10
<b>Number of Patents as Owner</b>	57
<b>Number of Patents as Third Party</b>	2
<b>Number of Deals</b>	6
<b>Key Indications</b>	Alzheimers disease,Hypertension,Atherosclerosis,Glaucoma,Metabolic syndrome X,Non-insulin dependent diabetes,Autoimmune disease,Dermatological disease,Cognitive disorder,Anxiety disorder,Diabetes mellitus,Neurodegenerative disease
<b>Key Target-based Actions</b>	Beta secretase 1 inhibitor,Liver X receptor beta agonist,11-Beta hydroxysteroid dehydrogenase 1 inhibitor,Renin inhibitor,Liver X receptor modulator,Retinoic acid receptor gamma antagonist,Aspartic protease inhibitor,Beta secretase inhibitor,Beta amyloid antagonist,Retinoid Z receptor gamma antagonist
<b>Key Technologies</b>	Small molecule therapeutic,Oral formulation,Crystalline form,Salt synthesis

## COMPANY PROFILE

### SUMMARY

Vitae Pharmaceuticals (formerly Concurrent Pharmaceuticals), based in Fort Washington, PA and founded in May 2001, is a clinical-stage biopharmaceutical company focused on innovative drug discovery and development of small molecules in the areas of chronic kidney disease, diabetes, atherosclerosis and Alzheimer's disease. In January 2005, the company changed its name from Concurrent to Vitae.

### LICENSING AGREEMENTS

In May 2007, Quest licensed Vitae's selective retinoic acid receptor agonists and antagonists and rexinoids for cancer. Quest also acquired a technology platform, intellectual property and a small molecule library.

In May 2004, Concurrent acquired rights to certain of Allergan Inc's preclinical programs and its retinoid and rexinoid nuclear receptor research portfolio.

### FINANCIAL

In January 2015, the company initiated a proposed follow-on public offering of 3 million shares of its common stock. At that time, the company expected to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares. In January 2015, the company priced its follow-on public offering at \$11.90 per share, with underwriters granted the 30-day purchase option. At that time, the offering was expected to close on or about January 28, 2015. later that month, the public offering was closed and the company planned to raise aggregate net proceeds of approximately \$37.8 million. A total of 3,450,000 shares of its common stock were sold at \$11.90 per share.

In December 2014, the company was added to the Russell 2000 and 3000 indices.

In September 2014, the company priced its initial public offering of 6,875,000 shares of common stock at \$8.00 per share and the underwriters were granted a 30-day option to purchase up to an additional 1,031,250 shares of common stock at the initial public offering price to cover any over-allotments. By that time, the shares began trading on NASDAQ global market under the ticker symbol "VTAE". Later that month, the offering was closed and the company planned to raise aggregate net proceeds of approximately \$48.4 million. In October 2014, the underwriters fully exercised their option to purchase the additional shares at \$8.00 each, and expected to raise net proceeds of approximately \$56 million.

[Return to Table of Contents](#)



In January 2012, the company secured a \$15 million senior credit facility from Oxford Finance and Silicon Valley Bank.

In October 2008, Vitae entered into a \$13 million loan agreement. The company planned to use the funds to support the initial clinical development of its renin inhibitor program and to support the ongoing development of its BACE program.

By August 2006, Vitae's investors included Prospect Venture Partners, Venrock Associates, New Enterprise Associates, Atlas Venture, Wellcome Trust, Intel Capital and Allergan Corporation.

In January 2005, Vitae secured \$34 million in equity financing, which would be used to accelerate the company's programs and to advance them into clinical trials.


In January 2004, Concurrent completed a series B preferred stock financing totaling \$15 million.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Dermatological disease	1	4	5
Neurological disease	2	1	3
Degeneration	2	1	3
Metabolic disorder	2	1	3
Neoplasm	0	3	3
Immune disorder	1	2	3
Cardiovascular disease	2	0	2
Endocrine disease	1	1	2
Hematological disease	0	2	2
Gastrointestinal disease	1	1	2
Nutritional disorder	0	1	1
Toxicity and intoxication	0	1	1
Respiratory disease	0	1	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Phase 1 Clinical	2
Discovery	4
Discontinued	3
No Development Reported	7

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Asset Divestment	0	0	1	0	1
Drug - Development/Commercialization License	2	0	0	0	4
Drug - Manufacturing/Supply	0	0	1	0	1

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Cardiovascular disease	0	1
Immune disorder	0	1
Dermatological disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	0	1
Phase 1	0	3

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)





## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	51	0	51
Endocrine disease	38	0	38
Gastrointestinal disease	25	0	25
Genitourinary disease	20	0	20
Growth disorder	15	0	15
Hematological disease	7	0	7
Degeneration	21	0	21
Immune disorder	12	0	12
Psychiatric disorder	36	0	36
Musculoskeletal disease	10	0	10
Neoplasm	11	0	11
Ocular disease	40	0	40
Metabolic disorder	45	0	45
Neurological disease	42	0	42
Nutritional disorder	19	0	19
Respiratory disease	8	0	8
Infectious disease	6	0	6
Injury	5	0	5
Toxicity and intoxication	1	0	1
Inflammatory disease	12	0	12
Gynecology and obstetrics	5	0	5
Dermatological disease	11	0	11

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### VTP-34072

#### VTP-34072 SNAPSHOT

<b>Drug Name</b>	VTP-34072
<b>Key Synonyms</b>	
<b>Originator Company</b>	Vitae Pharmaceuticals Inc
<b>Active Companies</b>	Boehringer Ingelheim Corp;Vitae Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Non-insulin dependent diabetes;Metabolic syndrome X
<b>Target-based Actions</b>	11-Beta hydroxysteroid dehydrogenase 1 inhibitor
<b>Other Actions</b>	Hypoglycemic agent
<b>Technologies</b>	Oral formulation;Small molecule therapeutic
<b>Last Change Date</b>	13-Nov-2014

#### VTP-34072 DEVELOPMENT PROFILE

##### SUMMARY

Vitae Pharmaceuticals and Boehringer Ingelheim are developing inhibitors of 11-beta hydroxysteroid dehydrogenase-1 (11-beta HSD-1) including VTP-34072 (BI-135585; BI-135585-XX), for the potential oral treatment of type 2 diabetes,. The companies are also investigating the program for other metabolic syndrome related indications . In January 2012, development was ongoing for other metabolic syndrome related indications ; in March 2013, this was still the case. In July 2014, the company in collaboration with Boehringer Ingelheim initiated a phase II trial. At that time, results were expected in the first half of 2015.

The companies were previously investigating the drug for obesity ; however, no further development was reported since June 2010.

#### VTP-34072 DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Boehringer Ingelheim Corp	Non-insulin dependent diabetes	Germany	Phase 2 Clinical	31-Jul-2014
Vitae Pharmaceuticals Inc	Non-insulin dependent diabetes	US	Phase 2 Clinical	31-Jul-2014
Boehringer Ingelheim Corp	Metabolic syndrome X	Germany	Discovery	15-Oct-2007


[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Vitae Pharmaceuticals Inc	Metabolic syndrome X	US	Discovery	15-Oct-2007
Boehringer Ingelheim Corp	Obesity	Germany	No Development Reported	07-Dec-2011
Vitae Pharmaceuticals Inc	Obesity	US	No Development Reported	07-Dec-2011


## VTP-34072 CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	3
 <p>The chemical structure of VTP-34072 is a complex molecule. It features a central piperidine ring. One nitrogen of the piperidine is part of a carbamate group, which is further substituted with a 4-fluorophenyl group and a 2-hydroxyethyl group. The other nitrogen of the piperidine is substituted with a 4-(2,4-difluorophenyl)phenyl group.</p>	

CAS Registry Number:	Confidence Level:
	4
 <p>The chemical structure of VTP-34072 is a complex molecule. It features a central piperidine ring. One nitrogen of the piperidine is part of a carbamate group, which is further substituted with a 4-fluorophenyl group and a 2-hydroxyethyl group. The other nitrogen of the piperidine is substituted with a 4-(2,4-difluorophenyl)phenyl group.</p>	

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
	3
	

### VTP-34072 DRUG NAMES

Names	Type
VTP-34072	Research Code
11-beta hydroxysteroid dehydrogenase-1 inhibitors (metabolic disorders), Vitae/Boehringer Ingelheim	
11-beta HSD-1 inhibitors (metabolic disorders), Vitae/Boehringer Ingelheim	
BI-135585-XX	Research Code
BI-135585	Research Code

### VTP-34072 CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Non-insulin dependent diabetes											
0	0	0	0	0	0	0	4	0	0	0	4

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	5	0	0	0	5

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

VTP-34072 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Boehringer Ingelheim Corp	0	0	1	0	1
Vitae Pharmaceuticals Inc	1	0	0	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

## VTP-27999

### VTP-27999 SNAPSHOT

Drug Name	VTP-27999
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Vitae Pharmaceuticals Inc
Inactive Companies	GlaxoSmithKline plc
Highest Status	Phase 1 Clinical
Active Indications	Hypertension
Target-based Actions	Renin inhibitor
Other Actions	Antihypertensive
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	30-May-2014

### VTP-27999 DEVELOPMENT PROFILE

#### SUMMARY

Vitae is developing VTP-27999 (structure shown), an orally-active, small molecule alkyl amine, which acts as a renin inhibitor, for the potential treatment of hypertension in chronic kidney disease patients,. A phase I trial began in September 2009 ; in October 2010, preliminary results were reported. In September 2013, the drug was listed as being in phase I development and at that time, a phase IIb study was planned to initiate in 2014. In May 2014, the company was seeking to outlicense the drug to initiate phase IIb studies.

GlaxoSmithKline (GSK) previously held rights to codevelop the program; however, in October 2008, Vitae reacquired rights.

### VTP-27999 DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Vitae Pharmaceuticals Inc	Hypertension	US	Phase 1 Clinical	21-Sep-2009
GlaxoSmithKline plc	Hypertension	UK	Discontinued	21-Oct-2008


### VTP-27999 CHEMICAL STRUCTURES

[Return to Table of Contents](#)




CAS Registry Number:	Confidence Level:
	4
	
Name	Type
VTP-27999	Research Code


CAS Registry Number:	Confidence Level:
	5
	

CAS Registry Number:	Confidence Level:
	3
	

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
	4
	

CAS Registry Number:	Confidence Level:
	3
	

### VTP-27999 DRUG NAMES

Names	Type
renin inhibitors (oral, hypertension), Vitae	
VTP-27999	Research Code

### VTP-27999 CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All

Hypertension											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	3	0	0	0	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

VTP-27999 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Vitae Pharmaceuticals Inc	0	1	0	0	1
GlaxoSmithKline plc	0	0	0	1	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	0	1	1

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Vitae Pharmaceuticals Inc	6	0	6
GlaxoSmithKline plc	1	4	5
Individual	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	4
Process	2

## VTP-37948

### VTP-37948 SNAPSHOT

Drug Name	VTP-37948
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Boehringer Ingelheim Corp;Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Alzheimers disease
Target-based Actions	Beta secretase 1 inhibitor
Other Actions	Neuroprotectant;Nootropic agent
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	27-Feb-2015

### VTP-37948 DEVELOPMENT PROFILE

#### SUMMARY

Vitae Pharmaceuticals, in collaboration with Boehringer Ingelheim, is developing VTP-37948 (BI-1181181), a lead from orally-active BACE (beta-secretase) inhibitors including BACE1 inhibitors, for the potential treatment of Alzheimer's disease (AD),. In February 2014, a phase I trial was initiated in Germany. In May 2014, a phase I trial was initiated in Belgium. In October 2014, top-line results from two phase I trials were reported. At that time, the company planned to initiate another phase I trial in Germany. In February 2015, the company had voluntarily placed a temporary clinical hold to further investigate skin reactions observed in some study participants during the multiple rising dose trial.

### VTP-37948 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Boehringer Ingelheim Corp	Alzheimers disease	Belgium	Phase 1 Clinical	19-May-2014
Boehringer Ingelheim Corp	Alzheimers disease	Germany	Phase 1 Clinical	20-Feb-2014
Vitae Pharmaceuticals Inc	Alzheimers disease	Belgium	Phase 1 Clinical	19-May-2014
Vitae Pharmaceuticals Inc	Alzheimers disease	Germany	Phase 1 Clinical	20-Feb-2014

[Return to Table of Contents](#)



VTP-37948 DRUG NAMES

Names	Type
beta-secretase inhibitors (oral, Alzheimer's disease), Vitae/Boehringer Ingelheim	
BACE inhibitor program (oral, Alzheimer's disease), Vitae Pharmaceuticals	
BACE1 inhibitors (oral, Alzheimer's disease), Vitae/Boehringer Ingelheim	
VTP-37948	Research Code
BI-1181181	Research Code



VTP-37948 CLINICAL TRIALS

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On- going	All	On- going	All	On- going	All	On- going	All	On- going	All	On- going	All
Total by Phase and Status											
0	0	0	0	0	0	2	4	0	0	2	4

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Boehringer Ingelheim Corp	0	0	1	0	1
Vitae Pharmaceuticals Inc	1	0	0	0	1

[Return to Table of Contents](#)



Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

## VTP-43742

### VTP-43742 SNAPSHOT

Drug Name	VTP-43742
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Autoimmune disease
Target-based Actions	Retinoic acid receptor gamma antagonist
Other Actions	Immunomodulator
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	30-Oct-2014

### VTP-43742 DEVELOPMENT PROFILE

#### SUMMARY

Vitae Pharmaceuticals is investigating VTP-43742, a lead from retinoid-acid receptor (RAR) related orphan receptor gamma t (ROR gamma t) inhibitors for the potential oral treatment of autoimmune disease,. In March 2013, the program was in lead optimization. In October 2014, an IND was expected to be filed with the US FDA in the first half of 2015 followed by a phase I trial. At that time, a phase I proof-of-concept trial in psoriasis patients was expected to be initiated in the second half of 2015, with results expected by the end of 2015. In March 2013, the company was seeking to outlicense the program .

### VTP-43742 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Vitae Pharmaceuticals Inc	Autoimmune disease	US	Discovery	21-Mar-2013

### VTP-43742 DRUG NAMES

Names	Type
retinoid-acid receptor-related orphan receptor gamma t inhibitors (autoimmune disease), Vitae ROR gamma t inhibitors (autoimmune disease), Vitae	
VTP-43742	Research Code

[Return to Table of Contents](#)



## VTP-38443

### VTP-38443 SNAPSHOT

Drug Name	VTP-38443
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Atherosclerosis
Target-based Actions	Liver X receptor beta agonist
Other Actions	Antiarteriosclerotic
Technologies	Small molecule therapeutic
Last Change Date	09-Jul-2014

### VTP-38443 DEVELOPMENT PROFILE

#### SUMMARY

Vitae Pharmaceuticals is investigating VTP-38443 (VTP-4), the lead from a small molecule selective partial Liver X Receptor (LXR) beta agonists for the potential treatment of atherosclerosis, . In October 2010, the program was listed as being in lead optimization ; in June 2012, the lead compound was in dose ranging toxicity studies. In September 2013, the program was listed as being in preclinical development and at that time, the company was seeking to outlicense the program.

The company is also investigating LXR modulator for dermatology and LXR modulator for Alzheimers disease.

### VTP-38443 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Vitae Pharmaceuticals Inc	Atherosclerosis	US	Discovery	29-Sep-2010

[Return to Table of Contents](#)



VTP-38443 DRUG NAMES

Names	Type
LXR modulators (atherosclerosis), Vitae Pharmaceuticals	
VTP-4	Research Code
Liver X Receptor modulators (atherosclerosis), Vitae Pharmaceuticals	
antiarteriosclerotic agents (small molecule therapeutics), Vitae Pharmaceuticals	
VTP-38443	Research Code
partial Liver X Receptor beta agonists (atherosclerosis), Vitae Pharmaceuticals	

[Return to Table of Contents](#)

## BIVP-1

### BIVP-1 SNAPSHOT

Drug Name	BIVP-1
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Boehringer Ingelheim Corp;Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Alzheimers disease
Target-based Actions	Beta secretase 1 inhibitor
Other Actions	Neuroprotectant;Beta amyloid synthesis inhibitor
Technologies	Small molecule therapeutic
Last Change Date	07-Aug-2014

### BIVP-1 DEVELOPMENT PROFILE

#### SUMMARY

Boehringer Ingelheim and Vitae Pharmaceuticals are investigating BIVP-1, a BACE1 inhibitor, for the potential treatment of Alzheimer's disease. In July 2014, preclinical data were presented.

### BIVP-1 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Boehringer Ingelheim Corp	Alzheimers disease	Germany	Discovery	16-Jul-2014
Vitae Pharmaceuticals Inc	Alzheimers disease	US	Discovery	16-Jul-2014

### BIVP-1 DRUG NAMES

Names	Type
BACE1 inhibitor (Alzheimer's disease), Vitae Pharmaceuticals\Boehringer Ingelheim	
BIVP-1	Research Code



[Return to Table of Contents](#)



BIVP-1 DEALS AND PATENTS

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Vitae Pharmaceuticals Inc	1	0	0	0	1
Boehringer Ingelheim Corp	0	0	1	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)



## VTP-38543

### VTP-38543 SNAPSHOT

Drug Name	VTP-38543
Key Synonyms	
Originator Company	Vitae Pharmaceuticals Inc
Active Companies	Vitae Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Dermatological disease
Target-based Actions	Liver X receptor modulator
Other Actions	Dermatological agent
Technologies	Small molecule therapeutic
Last Change Date	09-Jul-2014

### VTP-38543 DEVELOPMENT PROFILE

#### SUMMARY

Vitae Pharmaceuticals is investigating VTP-38543, a liver X receptor (LXR) modulator for the potential treatment of dermatological disease, including atopic dermatitis. In March 2013, the program was in preclinical development .

### VTP-38543 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Vitae Pharmaceuticals Inc	Dermatological disease	US	Discovery	21-Mar-2013

### VTP-38543 DRUG NAMES

Names	Type
LXR modulator (dermatological disease), Vitae	
liver X receptor modulator (dermatological disease), Vitae	
VTP-38543	Research Code

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

